Agios stops tebapivat blood cancer program after trial setback

Agios Pharmaceuticals stopped developing tebapivat for lower-risk myelodysplastic syndromes after a 65-patient mid-stage study failed to clear the company’s bar for advancement, a setback for patients who still face chronic anemia and repeated transfusions. The Cambridge, Massachusetts drugmaker’s shares fell 1.7% in morning trading after the announcement.

The Phase 2b trial tested three once-daily oral doses, 10 mg, 15 mg and 20 mg, over 24 weeks in patients with anemia. Agios said the main target was transfusion independence for at least eight consecutive weeks, a key measure in a disease where the bone marrow does not make enough healthy blood cells. The company said tebapivat showed biological activity, but not enough clinical benefit in a sufficient share of patients or subgroups to meet its predefined threshold. It also said the drug was generally well tolerated and that no new safety concerns emerged.

The result underscores how difficult lower-risk myelodysplastic syndromes remain to treat. MDS is a heterogeneous bone-marrow cancer marked by low blood counts, ineffective blood-cell production and, in some patients, progression to acute myeloid leukemia. The National Cancer Institute says MDS can be reclassified as AML when bone-marrow blasts reach at least 20%, and the American Cancer Society estimates roughly 10,000 U.S. cases a year, with risk rising sharply with age. Even lower-risk disease can cause severe anemia, repeated transfusions and a heavy quality-of-life burden, and many patients in Agios’s study had already received other treatments, which can cloud efficacy signals in small trials.

For patients waiting on another option, the program’s end leaves the treatment picture unchanged. Tebapivat belongs to a class of pyruvate kinase activators designed to help red blood cells function more effectively, but Agios will now keep it in a Phase 2 sickle cell disease trial, with topline data expected in the second half of 2026. That means the compound still has a path forward in a different blood disorder, even as its role in lower-risk MDS closes.

The setback does not erase Agios’s broader turnaround effort. The company already has AQVESME, its U.S. brand for mitapivat, rolling out after FDA approval on Dec. 23, 2025, for anemia in adults with alpha- or beta-thalassemia. Agios also said on May 22, 2026, that mitapivat was approved in the European Union for adults with thalassemia under the PYRUKYND name. For now, though, tebapivat’s missed MDS target is another example of how often promising mid-stage results fail to translate into a viable therapy.